Share new progress in development of vaccine for Alzheimer’s
July 20, 2016 at 9:12 am #18294biokitParticipant
Share a new progress in the development of vaccines for Alzheimer’s disease with you!
In a study which is published recently in the journal Scientific Reports, researchers from United States and Australia successfully targeted the brain pathology protein in the progression of Alzheimer’s disease, making the vaccines of Alzheimer’s disease be able to enter human test in the next 3 – 5 years.
Co-author of the study, Professor Nikolai Petrovsky from Australian Flinders University School of Medicine and his colleagues pointed out how the vaccine produces antibodies against the biomarkers in the brain of Alzheimer’s disease – β- amyloid and tau protein. The abnormal deposition of β-amyloid in the brain is one of the pathogenesis of Alzheimer’s disease. The aggregation of β- amyloid proteins would form sticky plaques, and the aggregation of tau proteins would form neurofibrillary tangles. If plaques and neurofibrillary tangle, it can cause abnormal nerve cell signaling, leading to nerve cell death.
Professor Petrovsky explained, "These proteins are just like cars in lanes and you need to remove them from the brain. Otherwise the broken car is left in the driveway, eventually you can’t get out. That’s what happened in patients with Alzheimer’s disease, for there are a lot of broken proteins in their brain."
<p>Professor Petrovsky noted that they have developed a "special" vaccine which is composed of MultiTEP vaccine platform and Advax MultiTEP. The team explained MultiTEP approach creates highly-reactive antibody response against β- amyloid and tau protein, while Advax is a complementary technology which can further promote antibody response. The researchers found that in a mouse model with Alzheimer’s disease, the vaccine was effective and well-tolerated without any adverse reaction reports. Vaccines can also conduct targeted therapy on pathological proteins in brain tissue of patients with Alzheimer’s.
Co-author of the study, Professor Anahit Ghochikyan of molecular medicine California institution noted, "This study shows that making use of our vaccines can help AD patients and even healthy people with high risk of AD produce immune response early. And if the disease proceeds, we can use another anti-tau protein vaccine to improve the effectiveness."
The researchers noted that they will conduct safety / non-clinical toxicity studies of the vaccine with four companies together in FDA clinical medicine project. If the vaccines remain successful in preclinical trials, they will conduct clinical study on patients with early Alzheimer’s disease or Alzheimer’s high-risk groups in the next 3 – 5 years.
- You must be logged in to reply to this topic.